Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC # 681239) and Bendamustine in Patients With Untreated Follicular Lymphoma

NCT01286272 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01286272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01286272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC # 681239) and Bendamustine in Patients With Untreated Follicular Lymphoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
April 28, 2011
Completion date
September 2, 2025
Enrollment
135 (actual)
Sites
96

Conditions

As the registry lists them; a condition with its own page is linked.

ann arbor stage iii grade 1 follicular lymphoma, ann arbor stage iii grade 2 follicular lymphoma, ann arbor stage iii grade 3 follicular lymphoma, ann arbor stage iv grade 1 follicular lymphoma, ann arbor stage iv grade 2 follicular lymphoma, ann arbor stage iv grade 3 follicular lymphoma, grade 3a follicular lymphoma